Secondary Outcome(s)
|
Proportion of patients with appropriate symptom screening
[Time Frame: Every 1-3 months for 12 months]
|
Feasibility of implementing differentiated care based on ART availability
[Time Frame: 12 months]
|
Access to care (time in days from positive symptom screen to appropriate referral)
[Time Frame: 12 months]
|
Research Costs (cost of conducting implementation science)
[Time Frame: 12 months]
|
Retention rate disaggregated by sex (male and female)
[Time Frame: 12 months]
|
Feasibility of implementing differentiated care from stakeholder perspectives
[Time Frame: 12 months]
|
Fidelity by monitoring the proportion of eligible patients successfully enrolled and retained in a model.
[Time Frame: 12 months]
|
Patient satisfaction using patient exit-survey
[Time Frame: 12 months]
|
Proportion of patients with appropriate laboratory monitoring through viral load testing
[Time Frame: 12 months]
|
Cost to patient based on semi-structured interviews
[Time Frame: 12 months]
|
Proportion of patients with appropriate laboratory monitoring (CD4 count testing)
[Time Frame: every 6 months for a year]
|
Efficiency (Difference between cost per additional patient retained and the cost per death averted divided by the difference in their effect)
[Time Frame: 12 months]
|
Activity Based Costing (cost per activity based on Time and Motion)
[Time Frame: 12 months]
|
Proportion of patients virally suppressed at one year among those exposed to the intervention compared to control conditions using mixed effects logistic regression
[Time Frame: 12 months]
|
Retention rate disaggregated by age (adult and adolescent)
[Time Frame: 12 months]
|